Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer Ag ADR (BAYRY)

Bayer Ag ADR (BAYRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 43,112,100
  • Shares Outstanding, K 3,930,000
  • Annual Sales, $ 51,552 M
  • Annual Income, $ -4,066 M
  • EBIT $ 1,828 M
  • EBITDA $ 9,427 M
  • 60-Month Beta 0.69
  • Price/Sales 0.85
  • Price/Cash Flow 2.94
  • Price/Book 1.26
  • Price/Earnings ttm 8.26
  • Earnings Per Share ttm 1.35
  • Most Recent Earnings $0.18 on 03/04/26
  • Next Earnings Date 05/12/26
  • Annual Dividend & Yield (Fwd) 0.02 (0.21%)
  • Most Recent Dividend 0.023 on 04/29/25
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.64
  • Number of Estimates 2
  • High Estimate 0.66
  • Low Estimate 0.62
  • Prior Year 0.65
  • Growth Rate Est. (year over year) -1.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.2500 +7.80%
on 03/04/26
12.5700 -12.09%
on 02/25/26
-1.4900 (-11.88%)
since 02/23/26
3-Month
10.2500 +7.80%
on 03/04/26
14.8500 -25.59%
on 02/17/26
+0.5100 (+4.84%)
since 12/23/25
52-Week
5.3000 +108.49%
on 04/07/25
14.8500 -25.59%
on 02/17/26
+4.5400 (+69.74%)
since 03/21/25

Most Recent Stories

More News
Bayer Crop Science Launches 2026 Opportunity Scholarship Program

Bayer Crop Science Canada is excited to support the future of Canadian agriculture with its 2026 Bayer Crop Science Opportunity Scholarship. Through the scholarship, students entering post-secondary...

BAYRY : 11.0500 (+0.73%)
BAYZF : 45.4550 (+2.41%)
BAYN : 0.0100 (unch)
KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

KERENDIA ® (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerular filtration rate (eGFR) slope from baseline...

BAYRY : 11.0500 (+0.73%)
BAYZF : 45.4550 (+2.41%)
BAYN : 0.0100 (unch)
New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions Expanded Tesla compatibility captures...

BAYRY : 11.0500 (+0.73%)
BAYZF : 45.4550 (+2.41%)
BAYN : 0.0100 (unch)
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

  225 Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration-resistant prostate cancer (mCRPC)...

BAYRY : 11.0500 (+0.73%)
BAYZF : 45.4550 (+2.41%)
BAYN : 0.0100 (unch)
Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

Final results for the key secondary endpoint of overall survival (OS) from the PEACE-3 trial will be presented by the European Organization for Research and Treatment of Cancer (EORTC) coalition as an...

BAYRY : 11.0500 (+0.73%)
BAYZF : 45.4550 (+2.41%)
BAYN : 0.0100 (unch)
Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA

Bayer files false advertising suit against J&J and Janssen Biotech Lawsuit seeks preliminary and permanent injunctions in addition to damages. This...

BAYRY : 11.0500 (+0.73%)
BAYZF : 45.4550 (+2.41%)
BAYN : 0.0100 (unch)
Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month

This February, the brand continues its See Your Risks initiative by challenging denial and bringing unseen heart health risk factors into view.

BAYRY : 11.0500 (+0.73%)
BAYZF : 45.4550 (+2.41%)
BAYN : 0.0100 (unch)
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign

‘Highlights REAL’ aims to spark vital conversations about advanced prostate cancer and educate about the importance of treatment management

BAYRY : 11.0500 (+0.73%)
BAYZF : 45.4550 (+2.41%)
BAYN : 0.0100 (unch)
Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada

Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada’s leadership in canola innovation by establishing a cutting-edge canola innovation centre. Located...

BAYRY : 11.0500 (+0.73%)
BAYZF : 45.4550 (+2.41%)
BAYN : 0.0100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses....

See More

Key Turning Points

3rd Resistance Point 11.8733
2nd Resistance Point 11.6567
1st Resistance Point 11.3533
Last Price 11.0500
1st Support Level 10.8333
2nd Support Level 10.6167
3rd Support Level 10.3133

See More

52-Week High 14.8500
Fibonacci 61.8% 11.2019
Last Price 11.0500
Fibonacci 50% 10.0750
Fibonacci 38.2% 8.9481
52-Week Low 5.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.